Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transcode Therapeutics Inc (NQ: RNAZ )

0.8848 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,334
Open 0.8848
Bid (Size) 0.8500 (1)
Ask (Size) 0.9000 (3)
Prev. Close 0.8848
Today's Range 0.8848 - 0.8848
52wk Range 0.1212 - 7.740
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. 
Via Benzinga

Performance

YTD
+448.20%
+448.20%
1 Month
+75.21%
+75.21%
3 Month
+33.64%
+33.64%
6 Month
+240.31%
+240.31%
1 Year
-85.49%
-85.49%

More News

Read More
Squarespace (SQSP) Stock Climbs 13% on $6.9 Billion Deal to Go Private
Via InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
Via InvestorPlace
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Looking Into TransCode Therapeutics's Recent Short Interest
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.